Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

BACKGROUND: Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phase IV AHEAD study was conducted to verify the safety and ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Jiang, Da, Zhang, Guifang, He, Yifu, Ba, Yi, Zhong, Haijun, Wang, Lin, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Wu, Xiangyuan, Gao, Feng, Sun, Guogui, Wu, Yongjuan, Ye, Feng, Wang, Qiong, Xie, Zhong, Yi, Tienan, Huang, Yong, Yu, Guohua, Lu, Lin, Yuan, Ying, Li, Wei, Liu, Likun, Sun, Yuping, Sun, Ying, Yin, Lifeng, Hou, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163723/
https://www.ncbi.nlm.nih.gov/pubmed/37147645
http://dx.doi.org/10.1186/s12916-023-02841-7

Ejemplares similares

Ejemplares similares